Skip to main content
Monday, November 16, 2026Nov 16

Celgene Corp. to pay $280M to settle cancer drug fraud suit

FILE - This April 7, 1998 file photo shows capsules of the drug thalidomide at the Celgene Corp. in Warren, N.J, printed with a symbol warning pregnant or soon-to-be pregnant women against use of the drug that had caused thousands of infant deformities. Celgene has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud by promoting a drug for leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday, July 25, 2017. (AP Photo/Mike Derer, File)
FILE - This April 7, 1998 file photo shows capsules of the drug thalidomide at the Celgene Corp. in Warren, N.J, printed with a symbol warning pregnant or soon-to-be pregnant women against use of the drug that had caused thousands of infant deformities. Celgene has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud by promoting a drug for leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday, July 25, 2017. (AP Photo/Mike Derer, File)

LOS ANGELES (AP) – Celgene Corp. has agreed to pay $280 million to settle a whistleblower lawsuit alleging the pharmaceutical company committed fraud promoting a drug with a notorious history that was re-purposed to treat leprosy and another therapy for unapproved cancer treatments, federal prosecutors announced Tuesday.

The agreement settled a lawsuit in Los Angeles federal court by a former Celgene saleswoman who said the New Jersey-based company submitted false claims to Medicare and health care programs in 28 states and Washington, D.C., which were all parties to the settlement.

“Patients deserve to know their doctors are prescribing drugs that are likely to provide effective treatment, rather than drugs marketed aggressively by pharmaceutical companies,” said Acting U.S. Attorney Sandra R. Brown.

The lawsuit filed by Beverly Brown was brought on behalf of the U.S. government under a federal whistleblower law. She could receive as much as $84 million as her share of the settlement.

Celgene denied wrongdoing and settled to avoid uncertainty, distraction and expensive litigation, the company said in a statement.